SECURITIES AND EXCHANGE COMMISSION
Schedule TO
(Rule 14d-100)
(AMENDMENT NO. 9)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
Ribapharm Inc.
Rx Acquisition
Corporation
a wholly owned subsidiary of
ICN Pharmaceuticals, Inc.
COMMON STOCK, PAR VALUE $.01 PER SHARE
(Title of Class of Securities)
762537108
(CUSIP Number of Class of Securities)
Gregory Keever, Esq.
Executive Vice President and Special Counsel to the Chairman
ICN Pharmaceuticals, Inc.
3300 Hyland Avenue
Costa Mesa, California 92626
(714) 545-0100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications on Behalf of the Filing Persons)
with a copy to:
Stephen F. Arcano, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square
New York, New York 10036-6522
(212) 735-3000
CALCULATION OF FILING FEE
| Transaction Valuation* | Amount of Filing Fee** | |||
$167,440,000 |
$ | 13,545.90 | ||
* Estimated for purposes of calculating the amount of the filing fee only. This calculation assumes the purchase of all outstanding shares (the “Shares”) of common stock, par value $.01 per share, of Ribapharm Inc., a Delaware corporation (the “Company”), not owned by ICN or its subsidiaries, at a purchase price of $5.60 per Share, net to the seller in cash. As of May 12, 2003, there were 150,000,000 shares of common stock of the Company outstanding, of which 120,100,000 shares are owned by ICN. As a result, this calculation assumes the purchase of 29,900,000 shares of common stock of the Company.
** The amount of the filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 11 issued by the Securities and Exchange Commission on February 21, 2003. Such fee equals .00809 percent of the value of the transaction.
| x | Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| Amount Previously Paid: | 13,545.90 | Filing Party: | ICN Pharmaceuticals, Inc. | |||||
| Form or Registration No.: | Schedule TO-T | Date Filed: | June 10, 2003 |
o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate boxes below to designate any transactions to which the statement relates:
x third-party tender offer subject to Rule 14d-1.
o issuer tender offer subject to Rule 13e-4.
x going-private transaction subject to Rule 13e-3.
o amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender offer: o
| Item 11. Additional Information. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| PRESS RELEASE | ||||||||
This Amendment No. 9 amends and supplements the Tender Offer Statement and Rule 13e-3 Transaction Statement filed under cover of Schedule TO with the Securities and Exchange Commission on June 10, 2003 by ICN Pharmaceuticals, Inc., a Delaware corporation (“ICN”), relating to the Offer (as defined below) to purchase all outstanding shares (the “Shares”) of common stock, par value $.01 per share, of Ribapharm Inc., a Delaware corporation (the “Company”), not owned by ICN or its subsidiaries, at a purchase price of $5.60 per Share, net to the seller in cash, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 10, 2003, and the related Letter of Transmittal (which, as amended or supplemented from time to time, together constitute the “Offer”).
Item 11. Additional Information.
Section (b) of Item 11 is amended and supplemented as follows: On July 15, 2003, ICN and the Company received a memorandum of decision and order (the “Ruling”), filed by Judge Mariana R. Pfaelzer of the United States District Court for the Central District of California on July 14, 2003, in the patent infringement suit brought by ICN and the Company (ICN Pharmaceuticals, Inc. and Ribapharm Inc. v. Geneva Pharmaceuticals Technology Corp., Teva Pharmaceuticals USA, Inc., and Three Rivers Pharmaceuticals, LLC (Case Nos. CV 02-3544-MRP (FMOx), consolidated with CV 02-3543-MRP (FMOx), CV 02-8142-MRP (FMOx) and CV 02-9358-MRP (FMOx))). In the Ruling, Judge Pfaelzer granted the defendants’ motion for summary judgment of non-infringement of the asserted patents concerning ribavirin and declined to rule on the defendants’ motion for summary judgment that such patents are invalid.
On July 16, 2003, ICN issued a press release (the “Press Release”) with respect to the Ruling. ICN stated in the Press Release that it is considering the implications of the Ruling with respect to the Offer. The full text of the Press Release is filed as Exhibit (a)(1)(xiii) hereto and is incorporated herein by reference.
Item 12. Exhibits.
(a)(1)(xiii) Press release issued by ICN on July 16, 2003.
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| RX ACQUISITION CORPORATION | ||||
| By: | /s/ Bary G. Bailey | |||
| Name: Bary G. Bailey Title: Vice President and Treasurer |
||||
| ICN PHARMACEUTICALS, INC. | ||||
| By: | /s/ Timothy C. Tyson | |||
| Name: Timothy C. Tyson Title: President and Chief Operating Officer |
||||
Date: July 16, 2003
INDEX TO EXHIBITS
(a)(1)(xiii) Press release issued by ICN on July 16, 2003.